Niagen Bioscience, Inc. (NAGE) stock
Close on Nov 17, 2026Market cap $161.42MP/E 17.0Yield –
Earnings
Niagen Bioscience's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Niagen Bioscience's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 3, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026after the close | – | – | – | – | Filing |
| Q2 FY2026ended Jun 30, 2026 | Aug 4, 2026during market hours | $29.80M | -4.2% | $0.01 | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026during market hours | $31.50M | +3.3% | $0.07 | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 4, 2026during market hours | $33.80M | +16.2% | $0.05 | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025during market hours | $34.00M | +32.8% | $0.05 | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025during market hours | $31.10M | +37.0% | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025during market hours | $30.50M | +37.4% | $0.06 | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 4, 2025during market hours | $29.10M | +37.3% | $0.09 | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 31, 2024during market hours | $25.60M | +31.3% | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 7, 2024during market hours | $22.70M | +11.8% | $0.00 | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024during market hours | $22.20M | -1.8% | -$0.01 | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 6, 2024during market hours | $21.20M | +1.0% | $0.00 | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 8, 2023during market hours | $19.50M | +14.0% | -$0.01 | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 9, 2023during market hours | $20.30M | +21.6% | -$0.03 | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 10, 2023during market hours | $22.60M | +30.6% | -$0.03 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 8, 2023during market hours | $21.00M | +18.0% | -$0.02 | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 2, 2022during market hours | $17.10M | -1.2% | -$0.01 | -$0.04 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 10, 2022during market hours | $16.70M | – | -$0.09 | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 12, 2022during market hours | $17.30M | – | -$0.11 | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 9, 2022during market hours | $17.80M | – | -$0.08 | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 3, 2021during market hours | $17.30M | – | -$0.13 | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 3, 2021during market hours | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021during market hours | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 10, 2021during market hours | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 4, 2020during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Niagen Bioscience's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| e-commerce business | FY2026 | +10% – +15% | +10% – +15% | Reaffirmed | Aug 4, 2026 |
| General & administrative | FY2026 | $3.00M – $4.00M | $4.00M – $5.00M | Lowered | May 6, 2026 |
Guidance vs results
The last range Niagen Bioscience gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue growth | +25% – +30% | +29.92%Σ4Q | Within range |
Guidance history
Every forecast Niagen Bioscience put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 4, 2026 | e-commerce business | FY2026 | +10% – +15% | Reaffirmed |
| May 6, 2026 | General & administrative | FY2026 | $3.00M – $4.00M | Lowered |
| May 6, 2026 | Net sales | FY2026 | +10% – +15% | Reaffirmed |
| Mar 4, 2026 | General & administrative | FY2026 | $4.00M – $5.00M | New |
| Mar 4, 2026 | Net sales | FY2026 | +10% – +15% | New |
| Nov 4, 2025 | General and administrative expenses | FY2025 | $8.00M – $9.00M | New |
| Nov 4, 2025 | net sales growth | FY2025 | +25% – +30% | New |
| Aug 6, 2025 | revenue growth | FY2025 | +22% – +27% | Raised |
| May 7, 2025 | Net sales growth | FY2025 | +20% – +25% | Raised |
| Mar 4, 2025 | General and administrative expenses | FY2025 | $5.00M – $6.00M | New |
| Mar 4, 2025 | revenue growth | FY2025 | +18% | New |
| Oct 31, 2024 | revenue growth | FY2024 | +15% | Raised |
| Aug 7, 2024 | general and administrative expense | FY2024 | $1.50M | Lowered |
| Aug 7, 2024 | revenue growth | FY2024 | +10% – +15% | Lowered |
| May 8, 2024 | increase in general and administrative expense | FY2024 | $1.50M – $2.50M | Reaffirmed |
| May 8, 2024 | net sales growth | FY2024 | +16% | New |
| Mar 6, 2024 | increase in general and administrative expense | FY2024 | $1.50M – $2.50M | New |
| Nov 8, 2023 | revenue growth | FY2023 | +14% – +16% | Reaffirmed |
| Aug 9, 2023 | revenue growth | FY2023 | +15% | Raised |
| May 10, 2023 | reduction in general and administrative expense | FY2023 | $1.00M – $2.00M | Lowered |
| May 10, 2023 | revenue growth | FY2023 | +12.5% | Raised |
| Mar 8, 2023 | reduction in general and administrative expense | FY2023 | $2.00M – $3.00M | New |
| Mar 8, 2023 | revenue growth | FY2023 | +10% | New |
| Nov 2, 2022 | gross margin | FY2022 | 60% | Reaffirmed |
| Nov 2, 2022 | increase in R&D | FY2022 | $1.00M | Reaffirmed |
| Nov 2, 2022 | decrease in general and administrative expense | FY2022 | $6.00M – $8.00M | Raised |
| Aug 10, 2022 | gross margin | FY2022 | 60% | Reaffirmed |
| Aug 10, 2022 | increase in R&D | FY2022 | $1.00M | Lowered |
| Aug 10, 2022 | decrease in general and administrative expense, as reported | FY2022 | $6.00M – $7.00M | Raised |
| May 12, 2022 | gross margin | FY2022 | 60% | Reaffirmed |
| May 12, 2022 | increase in research and development expense | FY2022 | $2.00M | Reaffirmed |
| May 12, 2022 | reduction in general and administrative expense | FY2022 | $5.00M – $6.00M | Reaffirmed |
| May 12, 2022 | revenue growth | FY2022 | +15% – +20% | Reaffirmed |
| Mar 9, 2022 | gross margin | FY2022 | 60% | New |
| Mar 9, 2022 | increase in research and development expense | FY2022 | $2.00M | New |
| Mar 9, 2022 | reduction in general and administrative expense | FY2022 | $5.00M – $6.00M | New |
| Mar 9, 2022 | revenue growth | FY2022 | +15% – +20% | New |
| Nov 3, 2021 | gross margin | FY2021 | 60% | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Niagen Bioscience filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- Results
- Results
- Update
- Update
- News
- Results
- Results
- Update
- Results
- Results
See a number that looks wrong?